International Scholarly Research Notices

Clinical Study

In Crohn's Disease, Anti-TNF- 𝜶 Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells

Table 1

Patient characteristics.
𝑛
Gender: female/male6/7 (46/54%)
Disease type
 Inflammatory6 (46%)
 Stricturing4 (31%)
 Inflammatory + perianal3 (23%)
Disease location
 Ileum2 (15%)
 Colon3 (23%)
 Ileocolon8 (62%)
Medication (at first endoscopy)
 Azathioprine or 6-9 (69%)
 mercaptopurin2 (15%)
 Methotrexate9 (69%)
 Corticosteroids9 (69%)
 Mesalamine2 (15%)
 Salazosulphapyridine1 (8%)
 Metronidazole
Medication (at second endoscopy)
 Azathioprine or 6-11 (85%)
 mercaptopurin2 (15%)
 Methotrexate0 (0%)
 Corticosteroids8 (62%)
 Mesalamine2 (15%)
 Salazosulphapyridine0 (0%)
 Metronidazole
Previous anti-TNF- 𝛼 4 (31%)
treatment
Median (range)
Age, years,23 (19–44)
Disease duration, years5.1 (0.4–27.0)
CDEIS
 Before treatment14.4 (1.8–25.3)
 After treatment4.4 (0.0–11.2), 𝑃 = 0 . 0 0 6
CDAI
 Before treatment174 (50–605)
 After treatment64 (24–112), 𝑃 = 0 . 0 0 3
Fecal calprotectin 𝜇 g/g
 Before treatment1173 (88–15326)
 After treatment127 (13–1419), 𝑃 = 0 . 0 0 2
Serum CRP
 Before treatment ( 𝑛 = 1 0 ) 8 (<5–42)
 After treatment<5 (<5-6), 𝑃 = 0 . 0 1 2
CDAI: Crohn’s disease activity index; CDEIS: Crohn’s disease index of severity.